Quantcast

Latest Hyperammonemia Stories

2011-04-26 00:00:27

Children’s Memorial Hospital in Chicago is one of only 12 sites across the United States enrolling patients in a national clinical research trial which, for the first time is the United States, is using an investigational liver cell infusion to treat urea cycle disorders (UCDs) in children. UCDs are congenital and often life-threatening disorders of ammonia metabolism in the liver.

2011-04-14 14:48:00

WEINHEIM, Germany, April 14, 2011 /PRNewswire/ -- International biotechnology firm Cytonet recently launched the first ever clinical trial in the United States using an investigational liver cell infusion to treat urea cycle disorders (UCD) in children.

2010-12-15 07:00:00

SAN DIEGO, Dec. 15, 2010 /PRNewswire/ -- Ocera Therapeutics, Inc. announced today that it has completed two studies evaluating the safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) which includes healthy volunteers and patients with liver cirrhosis.

2010-03-18 13:32:00

SILVER SPRING, Md., March 18 /PRNewswire-USNewswire/ -- The U.S.

2009-11-02 07:00:00

BOSTON, Nov. 2 /PRNewswire/ -- UCL Liver Failure Group presented data from two studies with OCR-002 (L-ornithine phenylacetate) that suggest the potential for this novel therapeutic agent to impact multiple aspects of liver disease and its complications.

2009-06-30 07:00:00

SOUTH SAN FRANCISCO, Calif., June 30 /PRNewswire/ -- Hyperion Therapeutics, a privately held specialty pharmaceutical company focused on the development of therapies that address critical unmet needs in the areas of gastroenterology and hepatology, today announced it has closed a $60 million Series C financing.

2009-06-02 07:00:00

- Company preparing to initiate phase II trial in hepatic encephalopathy - SOUTH SAN FRANCISCO, Calif., June 2 /PRNewswire/ -- Hyperion Therapeutics, Inc. today announced top-line results from a phase I study of HPN-100 in patients with liver cirrhosis.

2009-05-05 07:00:00

- Company preparing to initiate phase III clinical trial - SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire/ -- Hyperion Therapeutics, Inc. today announced that HPN-100 has received orphan product designation from the U.S.

2009-03-30 07:00:00

- Company preparing to initiate phase III trial - SOUTH SAN FRANCISCO, Calif., March 30 /PRNewswire/ -- Hyperion Therapeutics, Inc. today announced top-line results from their phase II study of HPN-100 for the treatment of urea cycle disorders.


Word of the Day
quilisma
  • In medieval musical notation, a sign or neume denoting a shake or trill.
The word 'quilisma' comes from a Greek word meaning 'a roll'.